(Q36613394)

15 August 2017

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis (English)

1 reference

15 August 2017

phase III clinical trial

0 references

0 references

0 references

1 reference

ChEBI release 2020-05-28

5

Ludwig Kappos

1 reference

15 August 2017

10

Giancarlo Comi

1 reference

15 August 2017

Aaron E Miller

1

1 reference

15 August 2017

Paul O'Connor

2

1 reference

15 August 2017

Jerry S Wolinsky

3

1 reference

15 August 2017

Christian Confavreux

4

1 reference

15 August 2017

Tomas P Olsson

6

1 reference

15 August 2017

Philippe Truffinet

7

1 reference

15 August 2017

Lin Wang

8

1 reference

15 August 2017

Laura D'Castro

9

1 reference

15 August 2017

Mark S Freedman

11

1 reference

15 August 2017

Teriflunomide Multiple Sclerosis Trial Group

12

1 reference

15 August 2017

21 June 2012

1 reference

Multiple Sclerosis Journal

15 August 2017

1 reference

15 August 2017

18

1 reference

15 August 2017

11

1 reference

15 August 2017

1625-1632

1 reference

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573676

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573676

Review of teriflunomide and its potential in the treatment of multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573676

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573676

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573676

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573676

The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis--preliminary results.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573676

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1352458512450354

Short-term prognosis in early relapsing-remitting multiple sclerosis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22723573

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1352458512450354

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

22723573

1 reference